Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet Oncology

Volumn 18, Issue 12, 2017, Pages 1637-1651

  Bang, Yung Jue ^a   Xu, Rui Hua ^b   Chin, Keisho ^c   Lee, Keun Wook ^d   Park, Se Hoon ^e   Rha, Sun Young ^f   Shen, Lin ^g   Qin, Shukui ^h   Xu, Nong ⁱ   Im, Seock Ah ^a   Locker, Gershon ^j   Rowe, Phil ^j   Shi, Xiaojin ^j   Hodgson, Darren ^j   Liu, Yu Zhen ^j   Boku, Narikazu ^k  

^a Seoul National University College of Medicine   (South Korea)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d Seoul National University Bundang Hospital   (South Korea)

^e Sungkyunkwan University   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^h Nanjing Bayi Hospital   (China)

ⁱ ZHEJIANG UNIVERSITY   (China)

^j ASTRAZENECA   (United Kingdom)

^k NATIONAL CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OLAPARIB; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ALOPECIA; ANEMIA; ARTICLE; ASCITES; ASPIRATION PNEUMONIA; ASTHENIA; BONE MARROW DISEASE; CANCER COMBINATION CHEMOTHERAPY; CAUSE OF DEATH; CHOLANGITIS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; GRANULOCYTOPENIA; HUMAN; HYPERTENSION; HYPESTHESIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPROTEINEMIA; ILEUS; INTESTINE OBSTRUCTION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER INJURY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE ORGAN FAILURE; MYALGIA; NAUSEA; NEUTROPENIA; OBSTRUCTIVE JAUNDICE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; STOMACH CANCER; STOMACH OBSTRUCTION; TREATMENT RESPONSE; UREMIA; URINARY TRACT INFECTION; VOMITING; ASIA; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REMISSION; STOMACH TUMOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PACLITAXEL; PHTHALAZINES; PIPERAZINES; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85032965902     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30682-4     Document Type: Article

References (30)

1. International Agency for Research on Cancer. Globocan 2012: Stomach Cancer. http://gco.iarc.fr/today/fact-sheets-cancers?cancer=5&type=0&sex=0, 2012 (accessed Oct 10, 2017).
2. Rahman, R, Asombang, AW, Ibdah, JA, Characteristics of gastric cancer in Asia. World J Gastroenterol 20 (2014), 4483–4490.
3. Wilke, H, Muro, K, Van Cutsem, E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15 (2014), 1224–1235.
4. Hironaka, S, Ueda, S, Yasui, H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31 (2013), 4438–4444.
5. National Comprehensive Cancer Network. NCCN Guidelines for Gastric Cancer.1.2014 – Follow-up 04/29/14. https://www.google.co.uk/?gws_rd=ssl#q=NCCN+Guidelines+for+Gastric+Cancer.1.2014+%E2%80%93+Follow-up+04%2F29, 2014.
6. O'Connor, MJ, Targeting the DNA damage response in cancer. Mol Cell 60 (2015), 547–560.
7. Bang, YJ, Im, SA, Lee, KW, et al. Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. J Clin Oncol 33 (2015), 3858–3865.
8. Kurz, EU, Lees-Miller, SP, DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair 3 (2004), 889–900.
9. Goodarzi, AA, Jeggo, PA, The heterochromatic barrier to DNA double strand break repair: how to get the entry visa. Int J Mol Sci 13 (2012), 11844–11860.
10. Kim, HS, Kim, MA, Hodgson, D, et al. Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients. Pathobiology 80 (2013), 127–137.
11. AstraZeneca. Global Policy: Bioethics. https://www.astrazeneca.com/content/dam/az/PDF/Bioethics_policy.pdf, 2015 (accessed Oct 10, 2017).
12. Hochberg, Y, A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75 (1988), 800–802.
13. Efron, B, The efficiency of Cox's likelihood function for censored data. J Am Stat Assoc 72 (1977), 557–565.
14. Breslow, N, Covariance analysis of censored survival data. Biometrics 30 (1975), s89–s99.
15. Ray-Coquard, I, Selle, F, Harter, P, et al. PAOLA-1: an ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. Proc Am Soc Clin Oncol, 34(abstr), 2016, TPS5607.
16. Lowe, ES, Jayawardene, D, Penson, RT, SOLO3: a randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm). Proc Am Soc Clin Oncol, 34(abstr), 2016, TPS5598.
17. Golan, T, Oh, D-Y, Reni, M, et al. POLO: a randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm). Proc Am Soc Clin Oncol, 34(abstr), 2016, TPS4152.
18. Moore, KN, DiSilvestro, P, Lowe, ES, Garnett, S, Pujade-Lauraine, E, SOLO1 and SOLO2: randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm). Proc Am Soc Clin Oncol, 32(abstr), 2014, TPS5616.
19. Robson, M, Tutt, A, Balmana, J, et al. OlympiA, Neo-Olympia and OlympiAD: randomized phase III trials of olaparib in patients(pts) with breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). Cancer Res, 75, 2015 OT1 1 04.
20. Mateo, J, Moreno, V, Gupta, A, et al. An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Target Oncol 11 (2016), 401–415.
21. van der Noll, R, Ang, JE, Jager, A, et al. Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors. Proc Am Soc Clin Oncol, 31(abstr), 2013, 2579.
22. Hodgson, DR, Lai, Z, Dougherty, BA, et al. Candidate predictive biomarkers for response to olaparib in advanced gastric cancer (AGC). Proc Am Soc Clin Oncol, 34(abstr), 2016, 4041.
23. Kilgour, E, Angell, H, Kim, K-M, et al. Programmed death-ligand 1 (PD-L1) and immune infiltrates are prognostic for better outcome and enriched in the ATM (ataxia telangiectasia mutated)-low segment of gastric cancer (GC). Ann Oncol, 27, 2016, 624P.
24. Kim, JW, Im, SA, Kim, MA, et al. Ataxia-telangiectasia mutated (ATM) protein expression with microsatellite instability in gastric cancer as prognostic marker. Int J Cancer 134 (2014), 72–80.
25. Swisher, EM, Lin, KK, Oza, AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18 (2017), 75–87.
26. Mirza, MR, Monk, BJ, Herrstedt, J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375 (2016), 2154–2164.
27. Pujade-Lauraine, E, Ledermann, JA, Selle, F, et al. SOLO2/ENGOT-Ov21: a phase 3, randomised, double-blind, placebo-controlled trial of olaparib tablets as maintenance therapy in platinum-sensitive, relapsed ovarian cancer. Lancet Oncol 18 (2017), 1274–1284.
28. Robson, M, Im, SA, Senkus, E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377 (2017), 523–533.
29. Fong, PC, Yap, TA, Boss, DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28 (2010), 2512–2519.
30. US Food and Drug Administration. ABRAXANE® for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021660s031lbl.pdf, 2012 (accessed Oct 10, 2017).